Masayuki Yasugi

Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Hideko Isozaki, Eiki Ichihara, Nagio Takigawa et al. · Cancer Research · 2016 · 128 citations · Full text

Oncology, Medicine, Receptor Tyrosine Kinase +15

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer

Hiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya et al. · Japanese Journal of Clinical Oncology · 2019 · 74 citations

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

Nobuaki Ochi, Nagio Takigawa, Daijiro Harada et al. · Experimental Cell Research · 2014 · 47 citations

Medicine, Cancer Growth, Cancer Biology +8

<scp>JAK</scp>2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Daijiro Harada, Nagio Takigawa, Nobuaki Ochi et al. · Cancer Science · 2012 · 45 citations · Full text

Epidermal Growth Factor, Pathology, Jak2 Inhibitor +19

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

Kiichiro Ninomiya, Tae Hata, Hiroshige Yoshioka et al. · CHEST Journal · 2019 · 36 citations

Cancer Epidemiology, Medicine, Epidemiology Of Cancer +9